These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 15459428)

  • 41. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Rosen LS
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of bisphosphonates in cancer treatment.
    Coleman R
    Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault RL
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN
    Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    Coleman RE
    Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bisphosphonate therapy for patients with breast carcinoma.
    Plunkett TA; Rubens RD
    Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
    Powles T; McCroskey E; Paterson A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
    Migliorati CA; Schubert MM; Peterson DE; Seneda LM
    Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zoledronic acid (Zometa) use in bone disease.
    Theriault RL
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):157-66. PubMed ID: 12722875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonate treatment recommendations for oncologists.
    von Moos R
    Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should oral bisphosphonates be standard of care in women with early breast cancer?
    Clemons M; Verma S
    Breast Cancer Res Treat; 2005 Apr; 90(3):315-8. PubMed ID: 15830146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.